Effectiveness against symptomatic COVID-19 was 75% in previously infected participants and 31% among those never infected.
Trial: Alternative COVID vaccine 75% cross-protective against symptomatic cases in previously infected
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Global, US data show high antibiotic use, rise in resistant infections during COVID
- US respiratory virus levels continue to decline as officials track shift in SARS-CoV-2 proportions
- Study reveals promising results for abatacept for severe COVID
- Long-COVID patients more likely to report psychiatric symptoms, cost barriers to therapy